Merck & Company Inc (MRK)vsRani Therapeutics Holdings Inc (RANI)
MRK
Merck & Company Inc
$109.18
+2.73%
HEALTHCARE · Cap: $274.03B
RANI
Rani Therapeutics Holdings Inc
$0.94
+5.87%
HEALTHCARE · Cap: $108.42M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 3980978% more annual revenue ($65.01B vs $1.63M). MRK leads profitability with a 28.1% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
RANI
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-16.2%
Fair Value
$96.56
Current Price
$109.18
$12.62 premium
Margin of Safety
+62.9%
Fair Value
$3.37
Current Price
$0.94
$2.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Revenue surging 42.1% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : RANI
The strongest argument for RANI centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 42.1% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : RANI
The primary concerns for RANI are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while RANI is a hypergrowth play — different risk/reward profiles.
RANI carries more volatility with a beta of 0.66 — expect wider price swings.
RANI is growing revenue faster at 42.1% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 31/100), backed by strong 28.1% margins. RANI offers better value entry with a 62.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Rani Therapeutics Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rani Therapeutics Holdings Inc. is a pioneering biotechnology firm that revolutionizes injectable therapeutic delivery through its proprietary RaniPill™ technology, enabling the oral administration of biologics. This innovative platform not only enhances patient adherence but also improves treatment outcomes, effectively addressing critical gaps in the healthcare landscape. With a diverse pipeline targeting various therapeutic areas, Rani Therapeutics is well-positioned to disrupt conventional drug delivery methods while leveraging the increasing demand for non-invasive treatment solutions. Furthermore, the company's strategic collaborations and strong emphasis on research and development highlight its potential for substantial growth and meaningful contributions to the pharmaceutical sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?